## WYE-687 dihydrochloride

MedChemExpress

Cat. No.:	HY-15271A	
CAS No.:	1702364-87-1	
Molecular Formula:	C <sub>28</sub> H <sub>34</sub> Cl <sub>2</sub> N <sub>8</sub> O <sub>3</sub>	N N
Molecular Weight:	601.53	
Target:	mTOR; PI3K	
Pathway:	PI3K/Akt/mTOR	
Storage:	4°C, sealed storage, away from moisture	H-Ci
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

BIOLOGICAL ACTIVITY						
Description	WYE-687 dihydrochloride is an ATP-competitive mTOR inhibitor with an IC <sub>50</sub> of 7 nM <sup>[1]</sup> . WYE-687 dihydrochloride concurrently inhibits activation of mTORC1 and mTORC2 <sup>[2]</sup> . WYE-687 also inhibits PI3K $\alpha$ and PI3K $\gamma$ with IC <sub>50</sub> s of 81 nM and 3.11 $\mu$ M, respectively <sup>[1]</sup> .					
IC <sub>50</sub> & Target	mTOR 7 nM (IC <sub>50</sub> )	mTORC1	mTORC2	PI3K alpha 81 nM (IC <sub>50</sub> )		
	PI3K gamma 3.11 μΜ (IC <sub>50</sub> )	CK1 gamma1 17.8 μΜ (IC <sub>50</sub> )	p38 alpha 28.9 μΜ (IC <sub>50</sub> )			

## CUSTOMER VALIDATION

- Sci Rep. 2022 Apr 12;12(1):6090.
- Molecules. 2020 Apr 23;25(8):1980.
- Biosci Rep. 2019 Dec 20;39(12):BSR20191041.

See more customer validations on <a href="https://www.MedChemExpress.com">www.MedChemExpress.com</a>

## REFERENCES

[1]. Yu K, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009 Aug 1;69(15):6232-40.

[2]. Cheng F, et al. Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent. Biochem Biophys Res Commun. 2016 Feb 5;470(2):324-330.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA